Organization
RDO Pharmaceuticals
1 clinical trial
Clinical trial
Safety and Efficacy of 99mTc-hydrazinonicotinamide-PEG4-E[PEG4-c(RGDfk)]2 (99mTc-3PRGD2) for Integrin αVβ3 SPECT/CT Imaging of Lung Cancer and Mapping Lymph Node Metastases: A Prospective Multicenter, Self-controlled, Phase 3 TrialStatus: Completed, Estimated PCD: 2021-05-08